Drotaverine (hydrochloride) (Standard)

Drotaverine (hydrochloride) (Standard) is the analytical standard of Drotaverine (hydrochloride) . This product is intended for research and analytical applications. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.

Product Specifications

CAS Number

[985-12-6]

UNSPSC

12352100

Target

Calcium Channel; Phosphodiesterase (PDE) ; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Neurological Disease

Smiles

CCOC1=CC2=C(C=C1OCC)CCN/C2=C\C3=CC=C(OCC)C(OCC)=C3.[H]Cl

Molecular Formula

C24H32ClNO4

Molecular Weight

433.97

References & Citations

[1]Patai Z, Guttman A, Mikus EG. Assessment of the Airway Smooth Muscle Relaxant Effect of Drotaverine. Pharmacology. 2018;101 (3-4) :163-169. |[2]Zsuzsanna Tömösközi, et al. Drotaverine interacts with the L-type Ca (2+) channel in pregnant rat uterine membranes. Eur J Pharmacol. 2002 Aug 2;449 (1-2) :55-60.|[3]Samra Nazir, et al. Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice. Neurochem Res. 2021 Jul;46 (7) :1814-1829.|[4]Athanas D. Kristev, et al. Comparing hyoscine and drotaverine effects on colon in CT colonography. Cent. Eur. J. Med.6 (2) . 2011 . 234-242|[5]Ioana Z Pavel, et al. Drotaverine - a Concealed Cytostatic!.Arch Pharm (Weinheim) . 2017 Jan;350 (1) .